LON:HIK Hikma Pharmaceuticals (HIK) Share Price, News & Analysis GBX 1,956 -36.00 (-1.81%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range 1,955▼ 2,00250-Day Range 1,809▼ 2,08852-Week Range 1,711▼ 2,165Volume230,986 shsAverage Volume542,482 shsMarket Capitalization£4.34 billionP/E Ratio3,009.23Dividend Yield3.17%Price TargetGBX 2,325 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability Get Hikma Pharmaceuticals alerts: Email Address Hikma Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside18.9% UpsideGBX 2,325 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainability-2.61Upright™ Environmental ScoreNews Sentiment0.51Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.34 out of 5 stars 2.3 Analyst's Opinion Consensus RatingHikma Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageHikma Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Hikma Pharmaceuticals' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for HIK. Previous Next 0.8 Dividend Strength Dividend YieldHikma Pharmaceuticals pays a meaningful dividend of 3.15%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthHikma Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Hikma Pharmaceuticals is 9,538.46%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about Hikma Pharmaceuticals' dividend. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHikma Pharmaceuticals has received a 48.26% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Abiraterone", "Cancer medication (L01)", "Isosorbide dinitrate", and "HIV medication" products. See details.Environmental SustainabilityThe Environmental Impact score for Hikma Pharmaceuticals is -2.61. Previous Next 2.0 News and Social Media Coverage News SentimentHikma Pharmaceuticals has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Hikma Pharmaceuticals this week, compared to 2 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hikma Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders30.54% of the stock of Hikma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.47% of the stock of Hikma Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Hikma Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Hikma Pharmaceuticals is 3,009.23, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 128.08.Price to Earnings Ratio vs. SectorThe P/E ratio of Hikma Pharmaceuticals is 3,009.23, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 114.96.Price to Earnings Growth RatioHikma Pharmaceuticals has a PEG Ratio of 2.38. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHikma Pharmaceuticals has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. About Hikma Pharmaceuticals Stock (LON:HIK)Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.Read More HIK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HIK Stock News HeadlinesSeptember 6 at 2:52 AM | msn.comUS Allows ADHD Drugmaker To Increase Production Limit To Ease Ongoing ShortageSeptember 4 at 12:09 PM | finance.yahoo.comHikma Pharmaceuticals (LON:HIK) shareholders have endured a 17% loss from investing in the stock three years agoSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.September 4 at 1:59 AM | americanbankingnews.comHikma Pharmaceuticals (LON:HIK) Rating Increased to Buy at Berenberg BankSeptember 3, 2024 | marketwatch.comHikma Pharmaceuticals falls Tuesday, still outperforms marketSeptember 3, 2024 | lse.co.ukLONDON BROKER RATINGS: Berenberg raises Hikma Pharmaceuticals to 'buy'September 1, 2024 | americanbankingnews.comHikma Pharmaceuticals PLC (LON:HIK) Given Consensus Recommendation of "Moderate Buy" by BrokeragesAugust 12, 2024 | msn.comFTSE outperforms European peers after oil prices riseSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 12, 2024 | markets.businessinsider.comFTSE 100 Rises Ahead Of Key Economic DataAugust 12, 2024 | marketwatch.comHikma Pharmaceuticals falls Monday, underperforms marketAugust 11, 2024 | finance.yahoo.comHikma Pharmaceuticals First Half 2024 Earnings: Beats ExpectationsAugust 11, 2024 | finance.yahoo.comHikma Pharmaceuticals PLC Just Beat EPS By 12%: Here's What Analysts Think Will Happen NextAugust 8, 2024 | msn.comLondon's FTSE 100 inches lower as companies trade ex-dividend; earnings cap declinesAugust 8, 2024 | msn.comSTOXX 600 recovers early losses on US jobs data reliefAugust 8, 2024 | msn.comLondon's FTSE 100 ends lower as top companies trade ex-dividendMay 17, 2024 | finanznachrichten.deActive Pharmaceutical Ingredient Market Worth $238.3 billion | MarketsandMarketsApril 26, 2024 | markets.businessinsider.comEuropean Stocks Close On Strong Note As Investors Cheer Earnings UpdatesSee More Headlines Receive HIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 9/20 Dividend8/15/2024Today9/07/2024Dividend Payable9/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:HIK CUSIPN/A CIKN/A Webwww.hikma.com Phone+44-20-73992760FaxN/AEmployees9,100Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 2,325 High Stock Price TargetGBX 2,750 Low Stock Price TargetGBX 2,000 Potential Upside/Downside+18.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 0.65 Trailing P/E Ratio3,009.23 Forward P/E Ratio12.62 P/E Growth2.38Net Income£285 million Net Margins9.45% Pretax MarginN/A Return on Equity12.88% Return on Assets9.40% Debt Debt-to-Equity Ratio55.48 Current Ratio1.66 Quick Ratio1.27 Sales & Book Value Annual Sales£3.02 billion Price / Sales1.44 Cash FlowGBX 234.56 per share Price / Cash Flow8.34 Book ValueGBX 1,031 per share Price / Book1.90Miscellaneous Outstanding Shares221,880,000Free FloatN/AMarket Cap£4.34 billion OptionableNot Optionable Beta0.41 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesEngineer Said Samih Taleb Darwazah (Age 67)Executive Chairman Comp: $2.21MMr. Riad Ali Mishlawi (Age 60)CEO & Director Comp: $869.23kMr. Mazen Samih Taleb Darwazah (Age 66)Executive Vice Chairman & President of MENA Comp: $1.81MMr. Khalid Waleed Hosny Al Nabilsi (Age 52)Chief Financial Officer Patricia BousfieldChief Information OfficerMr. Guy FeatherstoneAssociate Director of Investor RelationsMr. Samuel ParkGeneral CounselMr. Bassam Wael Rushdi Kanaan CFA (Age 59)CPA, Executive Vice President of Corporate Development and M&A Mr. Hussein Omar ArkhaghaChief People OfficerMs. Susan RingdalExecutive Vice President of Strategic Planning & Global AffairsMore ExecutivesKey CompetitorsHUTCHMEDLON:HCMIndiviorLON:INDVAmryt PharmaLON:AMYTBenchmarkLON:BMKAlliance PharmaLON:APHView All CompetitorsInsidersRiad MishlawiBought 736 shares on 5/7/2024Total: £1.46 M ($1,979.00/share)View All Insider Transactions HIK Stock Analysis - Frequently Asked Questions How have HIK shares performed this year? Hikma Pharmaceuticals' stock was trading at GBX 1,789 at the beginning of the year. Since then, HIK stock has increased by 9.3% and is now trading at GBX 1,956. View the best growth stocks for 2024 here. How do I buy shares of Hikma Pharmaceuticals? Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Hikma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hikma Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW) and Athabasca Oil (ATH). This page (LON:HIK) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HIK Stock Alerts